Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842484 | 0.88 | NOTUM (0.40) | ALDH1A1MAPK1GPBAR1STAT3SMN1; SMN2 | |
| SCHEMBL842521 | 0.81 | CYP11B2 (0.43) | MAPK1SMN1; SMN2P2RY1CACNA1G | |
| SCHEMBL842507 | 0.80 | CACNA1H (0.41) | ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL9493247 | 0.77 | CYP11B2 (0.43) | ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL2817700 | 0.77 | CYP11B2 (0.43) | ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL9493435 | 0.77 | CYP11B2 (0.43) | ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL10494022 | 0.76 | KMT2A (0.48) | MAPK1MEN1KMT2A | |
| SCHEMBL843562 | 0.75 | KMT2A (0.43) | ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL2818685 | 0.74 | KDM4C (0.44) | ALDH1A1HPGDMAPK1 | |
| SCHEMBL9673472 | 0.74 | MAPK1 (0.40) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093711-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP11B2 | ALDH1A1 142/4885HPGD 202/4885MAPK1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.